Table 1: Evolution of prevalence and means of cardiometabolic risk factors during the four-year follow-up period ( ).

Risk factorsAllWomen ( )Men ( )
Baseline4 years Baseline4 years Baseline4 years

Systolic BPb (mmHg) <0.001 <0.001 <0.001
Diastolic BPb (mmHg) <0.001 <0.001 <0.001
High BPc35.121.6<0.00119.514.90.15118.311.10.037
FGd (mmol/L) <0.001 0.039 0.002
High FGe9.620.0<0.00110.117.30.0329.122.6<0.001
HDL-C (mmol/L) <0.001 <0.001 0.023
Low HDL-C26.237.7<0.00131.247.1<0.00121.228.40.088
TC/HDL-C <0.001 <0.001 <0.001
High TC/HDL13.722.6<0.00118.828.80.0158.716.30.017
TG (mmol/L) <0.001 <0.001 <0.001
High TG2.28.7<0.0011.08.7<0.0013.412.0<0.001
WC (cm) 0.034 <0.001 0.038
Abdominal obesity42.542.30.94469.265.90.46315.918.80.436
Body mass index <0.001 <0.001 <0.001
Overweight (%)23.824.30.87130.826.00.27616.822.60.139
Overall obesity (%)7.211.30.04122.135.10.0035.87.20.550
MetS (%)8.713.90.01511.118.80.0276.29.10.269
FRS ≥ 10%7.211.30.0412.46.70.03412.015.90.257
MetS and FRS ≥ 10%2.44.30.1241.44.30.0783.44.30.610
MetS or FRS ≥ 10%13.520.90.00412.021.20.01214.920.70.123

Values are expressed as means ± SD or percentage.
BP: blood pressure, FG: fasting glycemia, HDL-C: high density lipoprotein cholesterol, TC: total cholesterol, WC: waist circumference, TG: triglycerides, MetS: metabolic syndrome, FRS: framingham risk score.
: for -test or test.
b33 subjects (23 women and 10 men) under medical treatment for high blood pressure are excluded.
cIncludes 33 subjects (23 women and 10 men) under medical treatment for high blood pressure.
d4 subjects (1 woman and 3 men) under medical treatment for diabetes are excluded.
eIncludes 4 subjects under treatment for diabetes.